Physician profile
Taylor Bevan
NPI 1033588504
$2,672.13
in general payments reported to CMS, 2019-2025
24 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $338 · 2022: $473 · 2023: $751 · 2024: $670 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,841 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,840.97 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $360.46 | 2022-2024 | Jardiance |
| Abbvie INC. | $342.66 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $318.57 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $297.27 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Teva Pharmaceuticals USA, INC. | $234.23 | 2021-2022 | |
| Glaxosmithkline, LLC. | $191.88 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $141.03 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Rhythm Pharmaceuticals, INC. | $113.06 | 2021 | |
| Medtronic, INC. | $78.62 | 2023 | Harmony |
| Exact Sciences Corporation | $78.22 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $73.84 | 2022-2023 | Xarelto |
| Pfizer INC. | $68.70 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $63.53 | 2022-2025 | |
| Dexcom, INC. | $59.68 | 2022-2023 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.67 | 2023-2025 | Xifaxan, Trulance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $33.89 | 2024-2025 | Recorlev |
| Sumitomo Pharma America, INC. | $33.46 | 2024-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $33.27 | 2022-2023 | |
| Ibsa Pharma INC. | $19.17 | 2024 | Licart, Tirosint |
| Dynavax Technologies Corporation | $18.66 | 2025 | Heplisav-B |
| Lundbeck LLC | $18.47 | 2023 | Vyepti |
| Astellas Pharma US INC | $17.26 | 2023 | Myrbetriq |
| Idorsia Pharmaceuticals US INC | $14.68 | 2023 | Quviviq |
| Ultragenyx Pharmaceutical INC. | $13.85 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Bevan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.